University of North Carolina at Greensboro

Consejo Superior De Investigaciones Cientificas

Temple University

Dow P Hurst

Patricia H Reggio

Derek M Shore

Nadine Jagerovic

Mary E Abood

Paula Morales Lazaro

Ana Lago Fernández

Pingwei Zhao

Nouroddin Sotoudeh Chafi

Eugen Brailoiu

Luciana Magalhaes Leo

The present invention relates to pyrazolylbenzene-1,3-diols as cannabidiol derivatives, its use for the manufacture of a medicament, and more particularly, to the use of this medicament for the treatment and/or prevention of a disorder associated with the GPR18 and/or TRPV1 receptors and the use of these compounds for pharmacological assays related to GPR18 and/or TRPV1.

Pyrazolylbenzene-1,3-diols for diseases associated with g protein-coupled receptor 18 and in combination with transient receptor potential vanilloid 1

The present invention provides compounds having a CBreceptor-binding moiety and a directing moiety. In related aspects, the invention provides pharmaceutical compositions containing compounds of the invention, methods for inhibiting a pathway modulated in part by the CBreceptor activity, and methods for treating a condition or disorder mediated in part by CBreceptor activity. In certain embodiments, the compounds are compounds of Formula I. Methods of preparing compounds of Formula I are also described. In another aspect, the invention provides methods of identifying a selective agonist of the beta-arrestin pathway over the G-protein pathway.

Beta-arrestin-biased cannabinoid CBreceptor agonists and methods for making and using them

Beta-arrestin-biased cannabinoid CB1 receptor agonists and methods for making and using them

Growing community of inventors

Greensboro, NC, United States of America

Dow P Hurst